Skip to content

    Recently Viewed



      Media Center

      Catch up on the latest Johnson & Johnson news and download the J&J logo and media assets here.

      At Johnson & Johnson our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal.

      Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow. We will combine our science and technology with our determination to create a powerful force of care ... and profoundly impact health for humanity.

      Highlighted press releases

      Our Company
      A photo of a Johnson & Johnson signature brick
      Our Company

      Johnson & Johnson MedTech Acquires Laminar, Inc.

      Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growth MedTech segments

      Johnson & Johnson highlights its preeminent leadership in hematology through differentiated blood cancer portfolio and pipeline with new clinical and real-world data at ASH

      Data highlights strength of multi-target, multi-platform multiple myeloma portfolio and continued innovation in B-cell malignancies to transform patient outcomes

      Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy

      The submission is supported by data from the Phase 3 MARIPOSA-2 study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of Oncology1,2 Amivantamab plus chemotherapy demonstrated significant improvements in progression-free survival, compared to chemotherapy alone, in patients with EGFR-mutated advanced non-small cell lung cancer following prior osimertinib therapy1

      Contact Global Media Relations

      Journalists please use the following Johnson & Johnson media relations contacts for inquiries.

      We recommend that if you are on deadline—or if it is after business hours—put ON DEADLINE in the subject of your email. It is also helpful if you are as specific as possible with your request.

      Office Telephone: 732-524-1090

      Media interviews

      Johnson & Johnson has a state-of-the-art production studio available for media interviews. We have an HD-SDI fiber optic cable connection to the All Mobile Video Gateway in Weehawken, New Jersey. From All Mobile Video Gateway, we can be patched to just about anywhere in the United States accessible by fiber optic cable. Our studio can also send our signal to an AMV uplink which allows for international video connections.

      Media assets for download

      All press releases

      Press Releases


      1,867 Results
      1,867 results
      You are now leaving and going to a site with a different privacy policy. Please click below to continue to that site.